

David Ternant

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9105896/david-ternant-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73
papers

2,378
citations

24
h-index

48
g-index

79
ext. papers

2,757
ext. citations

4.7
avg, IF

4.6
L-index

#	Paper	IF	Citations
73	Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. <i>Gastroenterology</i> , 2008 , 134, 1861-8	13.3	390
72	Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 948-55	27.4	242
71	Infliximab pharmacokinetics in inflammatory bowel disease patients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 523-9	3.2	143
70	Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2011 , 13, R105	5.7	109
69	Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. <i>Blood</i> , 2009 , 113, 3765-72	2.2	102
68	Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5 Suppl 1, S37-47	5.4	87
67	An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 169-74	3.2	86
66	Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 6329-37	12.9	77
65	Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 1107-23	6.2	72
64	Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. <i>Blood</i> , 2017 , 129, 2616-2623	2.2	57
63	Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 118-28	3.8	57
62	Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 286-97	3.8	51
61	Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 232-6	3.2	51
60	Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. <i>MAbs</i> , 2015 , 7, 1205-11	6.6	49
59	Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 551-62	6.2	43
58	IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding. <i>Journal of Immunology</i> , 2016 , 196, 607-13	5.3	41
57	Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 55-65	3.8	40

56	The underlying inflammatory chronic disease influences infliximab pharmacokinetics. <i>MAbs</i> , 2016 , 8, 1407-1416	6.6	37
55	Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1381-1394	6.2	34
54	Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R82	5.7	31
53	An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 597-601	3.2	30
52	An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 647-52	3.2	28
51	Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, e151-5	2.2	25
50	Pharmacokinetics of adalimumab in Crohn's disease. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1155-7	2.8	24
49	Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1773-1781	3.8	23
48	Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. <i>Transplant Immunology</i> , 2013 , 28, 120-6	1.7	22
47	Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 941-8	3.8	22
46	Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. <i>RMD Open</i> , 2020 , 6,	5.9	21
45	Towards an individualised target concentration of adalimumab in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1428-9	2.4	21
44	Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 169-187	6.2	20
43	Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 597-605	3.8	19
42	Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 322-326	3.2	18
41	Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia. <i>MAbs</i> , 2015 , 7, 630-7	6.6	18
40	Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 108-113	9.5	18
39	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2009 , 68, 561-73	3.8	17

38	Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 857-874	6.2	16
37	Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 364-369	3.2	16
36	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 635-647	6.2	16
35	P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment. <i>Cancers</i> , 2020 , 12,	6.6	13
34	Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 37-49	6.2	13
33	A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1541-2	2.8	12
32	Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 567-72	3.2	12
31	A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. <i>BMC Cancer</i> , 2017 , 17, 220	4.8	11
30	Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2002-2010	3.8	10
29	Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1173-1184	6.2	10
28	Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 339-343	3.2	9
27	A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 253-5	2.8	9
26	Influence of FcR11A genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 26-34	1.9	9
25	CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2747-2758	3.8	8
24	17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia 2019 , 7, 22		8
23	Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of FcgammaR11a genetic polymorphism. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 60-8	3.8	8
22	Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. <i>Bioanalysis</i> , 2017 , 9, 1227-1235	2.1	7
21	Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot Study. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1745-1754	4.5	7

20	Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study. <i>Haematologica</i> , 2018 , 103, e356-e359	6.6	5
19	CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. <i>Transplant International</i> , 2016 , 29, 184-95	3	5
18	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 519-530	6.2	5
17	Development and validation of an ELISA to study panitumumab pharmacokinetics. <i>Bioanalysis</i> , 2018 , 10, 205-214	2.1	3
16	Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab. <i>European Journal of Cancer</i> , 2018 , 92, 119-120	7.5	3
15	New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 722-728	3.8	3
14	Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2236-2246	3.8	3
13	Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer. <i>Clinical Nutrition</i> , 2020 , 39, 3319-3330	5.9	2
12	Gota et al. on their article "the pharmacokinetics of Reditux[α]a biosimilar of rituximab". <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 1317-1318	3.5	2
11	Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives. <i>Vaccines</i> , 2021 , 9,	5.3	1
10	Infliximab Treatment Does Not Lead to Full TNF- α Inhibition: A Target-Mediated Drug Disposition Model. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
9	Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
8	Intravenous and subcutaneous administration of trastuzumab in a patient on peritoneal dialysis. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3372-3374	3.8	1
7	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	0
6	A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations. <i>Bioanalysis</i> , 2021 , 13, 565-574	2.1	0
5	Letter to Dreesen et al. on their article "Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease"-A comprehensive review of infliximab population pharmacokinetic modelling publications. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1594-1595	3.8	0
4	Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 210-219	6.1	0
3	Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3160-3169	1.9	

- 2 Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients. *Clinical Pharmacokinetics*, **2021**, 1 6.2
- 1 Food and lipid intake alters the pharmacokinetics of cyclosporine in kidney transplants. *Fundamental and Clinical Pharmacology*, **2021**, 35, 446-454 3.1